#XFOR X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-reports-third-quarter-2026-financial-results-and-6d081y11qftt.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-reports-third-quarter-2026-financial-results-and-6d081y11qftt.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 9:15 PM
#XFOR X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-reports-third-quarter-2026-financial-results-and-6d081y11qftt.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-reports-third-quarter-2026-financial-results-and-6d081y11qftt.html?utm_source=stocktitan-bluesky&utm_medium=social
#XFOR X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-stifel-and-jefferies-2hkudcbmc8cd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-stifel-and-jefferies-2hkudcbmc8cd.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 management has two fireside chats and one presentation scheduled in November.
The schedule includes Nov. 10 and 12 fireside chats and a Nov. 16 corporate presentation; links to live and archived webcasts may be accessed under X4's Investors section.
www.stocktitan.net
November 3, 2026 at 9:30 PM
#XFOR X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-stifel-and-jefferies-2hkudcbmc8cd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-stifel-and-jefferies-2hkudcbmc8cd.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $XFOR
On October 29, 2026, X4 Pharmaceuticals, Inc. will be posting to its website an investor presentation to be used in the Company’s October 29, 2029 Investor Day event.
On October 29, 2026, X4 Pharmaceuticals, Inc. will be posting to its website an investor presentation to be used in the Company’s October 29, 2029 Investor Day event.
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 2:00 PM
🚨 $XFOR
On October 29, 2026, X4 Pharmaceuticals, Inc. will be posting to its website an investor presentation to be used in the Company’s October 29, 2029 Investor Day event.
On October 29, 2026, X4 Pharmaceuticals, Inc. will be posting to its website an investor presentation to be used in the Company’s October 29, 2029 Investor Day event.
#XFOR X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtu…
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-highlights-clinical-progress-and-market-9nrgks8683ib.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-highlights-clinical-progress-and-market-9nrgks8683ib.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
X4 Pharmaceuticals (XFOR) outlined clinical development milestones for mavorixafor in primary chronic neutropenia during its virtual Investor Day.X4 expects its 4WARD Phase 3 trial to complete target enrollment of 126 participants in Q4 2026. The planned 4STEPS Phase 2b trial will evaluate whether doses of granulocyte colony-stimulating factor (G-CSF), a treatment that increases neutrophils, can be safely reduced after starting mavorixafor while maintaining stable neutrophil counts.X4 expects first enrollment in 4STEPS in Q1 2027 and topline results from both trials in Q1 2028. Positive 4WARD results could support a regulatory submission, with potential FDA approval in late 2028 or early 2029. X4 estimates a U.S. market of approximately 15,000 patients, potentially expanding to approximately 30,000, subject to FDA labeling.
www.stocktitan.net
October 29, 2026 at 8:30 PM
#XFOR X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtu…
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-highlights-clinical-progress-and-market-9nrgks8683ib.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-highlights-clinical-progress-and-market-9nrgks8683ib.html?utm_source=stocktitan-bluesky&utm_medium=social
$MDLN-4 $SMCI-3 $KLAC-3 $TNA-3 $PYPL-3 $PURR-3 $PINS-3 $XLK-3 $AMKR-3 $HPQ-2 $PLTR-2 $KDP-2 $SOXX-2 $LITE-2 $VKTX-2 $ORCL-2 $SQQQ-2 $XFOR-2 $BA-2
October 29, 2026 at 8:47 PM
$MDLN-4 $SMCI-3 $KLAC-3 $TNA-3 $PYPL-3 $PURR-3 $PINS-3 $XLK-3 $AMKR-3 $HPQ-2 $PLTR-2 $KDP-2 $SOXX-2 $LITE-2 $VKTX-2 $ORCL-2 $SQQQ-2 $XFOR-2 $BA-2
Small-cap stocks with improving money flow, Tue Oct 27th - #$XFOR #$GRDX #$ULBI #$STAA #$RFIL #$EVGN #$DRH #$NUWE #$CPSH #$BGIN #$AEYE #$REF #$MAIR #$YALA #$OXM #$OI #$LVWR #$ENR #$CMP #$BAK - More: crystalequityresearch.com/leading-indi... - #smallcap
Leading Indicators, Tuesday October 27, 2028 – Crystal Equity Research
crystalequityresearch.com
October 27, 2026 at 11:47 PM
🚨 $XFOR
Craig Adam R (Executive Chairman) bought 4,600 shares at an average price of $2.5834 per common share. (Date: 2026-10-16)
Craig Adam R (Executive Chairman) bought 4,600 shares at an average price of $2.5834 per common share. (Date: 2026-10-16)
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
October 19, 2026 at 8:12 PM
🚨 $XFOR
Craig Adam R (Executive Chairman) bought 4,600 shares at an average price of $2.5834 per common share. (Date: 2026-10-16)
Craig Adam R (Executive Chairman) bought 4,600 shares at an average price of $2.5834 per common share. (Date: 2026-10-16)
X4 Pharmaceuticals ($XFOR) – Insider Purchase
• Insider: Adam R Craig, Chair
• Bought: 4,600 shares (about $12K)
• Price: about $2.58 a share · Oct 16
• Now Holds: 333,251 shares directly
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#InsiderBuying #Stocks
• Insider: Adam R Craig, Chair
• Bought: 4,600 shares (about $12K)
• Price: about $2.58 a share · Oct 16
• Now Holds: 333,251 shares directly
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#InsiderBuying #Stocks
Adam R Craig (Chair) bought $12K of X4 Pharmaceuticals ($XFOR)
Form 4 filed Oct 19. Every line of the filing.
elixstocks.com
October 19, 2026 at 8:07 PM
X4 Pharmaceuticals ($XFOR) – Insider Purchase
• Insider: Adam R Craig, Chair
• Bought: 4,600 shares (about $12K)
• Price: about $2.58 a share · Oct 16
• Now Holds: 333,251 shares directly
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#InsiderBuying #Stocks
• Insider: Adam R Craig, Chair
• Bought: 4,600 shares (about $12K)
• Price: about $2.58 a share · Oct 16
• Now Holds: 333,251 shares directly
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#InsiderBuying #Stocks
🚨 $XFOR
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
October 9, 2026 at 7:10 AM
🚨 $XFOR
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
$XRTX to file Health Canada CTA for XORLO in gout, boosting FDA NDA plans and partner interest; no deals signed yet. $IMNN $GNPX $XFOR $DNA $SXTC $ANNX $QNRX $MNDR $ESLA
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 10/09/26
export-download.canva.com
October 9, 2026 at 12:40 PM
$XRTX to file Health Canada CTA for XORLO in gout, boosting FDA NDA plans and partner interest; no deals signed yet. $IMNN $GNPX $XFOR $DNA $SXTC $ANNX $QNRX $MNDR $ESLA
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
#XFOR X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-host-virtual-investor-day-on-thursday-october-6t1v363jxvtr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-host-virtual-investor-day-on-thursday-october-6t1v363jxvtr.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 will outline a planned trial testing lower treatment doses while keeping white blood cell counts normal.
Management will review the Phase 3 4WARD trial and discuss mavorixafor for chronic neutropenia; the virtual event runs 10 a.m.–noon ET with expert Q&A.
www.stocktitan.net
October 9, 2026 at 11:00 AM
#XFOR X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-host-virtual-investor-day-on-thursday-october-6t1v363jxvtr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-host-virtual-investor-day-on-thursday-october-6t1v363jxvtr.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $XFOR
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
October 8, 2026 at 9:23 PM
🚨 $XFOR
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
On October 8, 2026, the Company issued a press release announcing its entry into the Loan Agreement.
#XFOR X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-secures-up-to-150-million-senior-debt-facility-stu49mjlb1uz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-secures-up-to-150-million-senior-debt-facility-stu49mjlb1uz.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 8, 2026 at 11:00 AM
#XFOR X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-secures-up-to-150-million-senior-debt-facility-stu49mjlb1uz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-secures-up-to-150-million-senior-debt-facility-stu49mjlb1uz.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals ($XFOR): 13G holder update
FMR LLC: now 4.6% (about $13M)
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
FMR LLC: now 4.6% (about $13M)
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
FMR LLC: 4.6% of X4 Pharmaceuticals ($XFOR)
Schedule 13G/A filed Oct 7. Who filed, the stake, and how it changed.
elixstocks.com
October 7, 2026 at 3:49 PM
X4 Pharmaceuticals ($XFOR): 13G holder update
FMR LLC: now 4.6% (about $13M)
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
FMR LLC: now 4.6% (about $13M)
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
🚨 $XFOR
KIRSKE DAVID (Chief Financial Officer) sold 11,767 shares at an average price of $2.8604 per common share. (Date: 2026-10-01)
KIRSKE DAVID (Chief Financial Officer) sold 11,767 shares at an average price of $2.8604 per common share. (Date: 2026-10-01)
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 8:09 PM
🚨 $XFOR
KIRSKE DAVID (Chief Financial Officer) sold 11,767 shares at an average price of $2.8604 per common share. (Date: 2026-10-01)
KIRSKE DAVID (Chief Financial Officer) sold 11,767 shares at an average price of $2.8604 per common share. (Date: 2026-10-01)
🚨 $XFOR
David Kirske, a Officer, filed a notice of intent to sell 11,767 shares of common stock, valued at approximately $33,658.47, on 10/01/2026.
David Kirske, a Officer, filed a notice of intent to sell 11,767 shares of common stock, valued at approximately $33,658.47, on 10/01/2026.
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
October 2, 2026 at 12:06 AM
🚨 $XFOR
David Kirske, a Officer, filed a notice of intent to sell 11,767 shares of common stock, valued at approximately $33,658.47, on 10/01/2026.
David Kirske, a Officer, filed a notice of intent to sell 11,767 shares of common stock, valued at approximately $33,658.47, on 10/01/2026.
#XFOR X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-wt7e570j5o2y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-wt7e570j5o2y.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) granted new employees options to purchase 80,000 common shares, effective September 30, 2026, as employment inducement awards.The options have an exercise price of $2.90 per share, equal to the stock's closing price on September 30, and a ten-year term. Vesting spans four years: 25% after 12 months, followed by monthly vesting over the next 36 months, subject to continued employment. The Compensation Committee approved the awards under the 2019 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
www.stocktitan.net
October 1, 2026 at 8:30 PM
#XFOR X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-wt7e570j5o2y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-wt7e570j5o2y.html?utm_source=stocktitan-bluesky&utm_medium=social
$CAPR-1 $JDZG-1 $AMJB-1 $ZUMZ-1 $XFOR-1 $CAH-1 $CVE-1 $EWY-1 $LOFF-1 $AXGN-1 $FTRE-1 $VXUS-1 $BOIL-1 $MRK-1 $DUK-1 $MNOV-1 $UPWK-1 $LUNR-1 $DT-1 $AMD-1 $BLTE-1 $GE-1 $KORU-1 $ALL-1
Daily Wrap - Final Message: Daily Wrap up for 2026-09-28 - 1344 events.
#burst_trades #HFT #trading ...
Daily Wrap - Final Message: Daily Wrap up for 2026-09-28 - 1344 events.
#burst_trades #HFT #trading ...
September 28, 2026 at 8:25 PM
$CAPR-1 $JDZG-1 $AMJB-1 $ZUMZ-1 $XFOR-1 $CAH-1 $CVE-1 $EWY-1 $LOFF-1 $AXGN-1 $FTRE-1 $VXUS-1 $BOIL-1 $MRK-1 $DUK-1 $MNOV-1 $UPWK-1 $LUNR-1 $DT-1 $AMD-1 $BLTE-1 $GE-1 $KORU-1 $ALL-1
Daily Wrap - Final Message: Daily Wrap up for 2026-09-28 - 1344 events.
#burst_trades #HFT #trading ...
Daily Wrap - Final Message: Daily Wrap up for 2026-09-28 - 1344 events.
#burst_trades #HFT #trading ...
Semenyo off xfor me. Appalling so far. Get Ndaie on
September 13, 2026 at 4:23 PM
Semenyo off xfor me. Appalling so far. Get Ndaie on
🚨 $XFOR
On September 8, 2026, X4 Pharmaceuticals, Inc. posted an updated corporate presentation on the Company’s website.
On September 8, 2026, X4 Pharmaceuticals, Inc. posted an updated corporate presentation on the Company’s website.
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
September 9, 2026 at 10:00 AM
🚨 $XFOR
On September 8, 2026, X4 Pharmaceuticals, Inc. posted an updated corporate presentation on the Company’s website.
On September 8, 2026, X4 Pharmaceuticals, Inc. posted an updated corporate presentation on the Company’s website.
#XFOR X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-2026-4gpz2ygp0yjz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-2026-4gpz2ygp0yjz.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 9, 2026 at 11:00 AM
#XFOR X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-2026-4gpz2ygp0yjz.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-2026-4gpz2ygp0yjz.html?utm_source=stocktitan-bluesky&utm_medium=social
BUY $XFOR (XFOR.O) [FDA] @ 11:00:07Z
September 8, 2026 at 11:00 AM
BUY $XFOR (XFOR.O) [FDA] @ 11:00:07Z
🚨 $XFOR
On September 8, 2026, X4 Pharmaceuticals, Inc. issued a press release announcing the positive outcome of the Company’s Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial.
On September 8, 2026, X4 Pharmaceuticals, Inc. issued a press release announcing the positive outcome of the Company’s Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial.
SEC Filing: XFOR
Click to view the official SEC document.
www.sec.gov
September 8, 2026 at 11:16 AM
🚨 $XFOR
On September 8, 2026, X4 Pharmaceuticals, Inc. issued a press release announcing the positive outcome of the Company’s Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial.
On September 8, 2026, X4 Pharmaceuticals, Inc. issued a press release announcing the positive outcome of the Company’s Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial.
#XFOR X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-positive-outcome-from-fda-type-c-so2hfm506282.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-positive-outcome-from-fda-type-c-so2hfm506282.html?utm_source=stocktitan-bluesky&utm_medium=social
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 8, 2026 at 11:00 AM
#XFOR X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-positive-outcome-from-fda-type-c-so2hfm506282.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-positive-outcome-from-fda-type-c-so2hfm506282.html?utm_source=stocktitan-bluesky&utm_medium=social